Medicinsk limning av lungsäcken
(2008)Department of Statistics
- Abstract
- A statistical analysis has been performed on a pharmacological study from the Lung department of Medical clinic, UsiL. The intention of the study was to explore, especially from a pallative aspect, treatment of exceptional fluid manifestations in pleura caused by cancer.
The patients were recruited between 1993 and 1997. They were randomized either to the drug Atabrine or to the drug Bleomycin. However due to the characteristics of the drugs it was not possible to perform this study as a double blind study. Except for an anomaly in one age group and in one gender group, we have found no signs or statistical indications that the randomization has been perfomed in an improper way. In this study it is the relapse rate that stands out.... (More) - A statistical analysis has been performed on a pharmacological study from the Lung department of Medical clinic, UsiL. The intention of the study was to explore, especially from a pallative aspect, treatment of exceptional fluid manifestations in pleura caused by cancer.
The patients were recruited between 1993 and 1997. They were randomized either to the drug Atabrine or to the drug Bleomycin. However due to the characteristics of the drugs it was not possible to perform this study as a double blind study. Except for an anomaly in one age group and in one gender group, we have found no signs or statistical indications that the randomization has been perfomed in an improper way. In this study it is the relapse rate that stands out. Patients treated with Bleomycin has a significant higher relapse rate than those treated with Atabrine (p=0.009). From a pallative aspect this is an important result.
With oddsratio over radiographic evidences of pleural disease there could be found a significant difference in lung quality between the two groups. Patients treated with Atabrine has a significant higher oddsratio, 1.62, to achieve the highest quality (p=0.0374).
The survival times could be followed all the way for all patients. No significant difference in the survival functions or the median survival times between the two treatments, Atabrine and Bleomycin, were found. (Less)
Please use this url to cite or link to this publication:
http://lup.lub.lu.se/student-papers/record/1644212
- author
- Arvastson, Per
- supervisor
- organization
- year
- 2008
- type
- M2 - Bachelor Degree
- subject
- keywords
- klinisk studie, oddskvot test, weibull-regression, överlevnadsanalys, Statistics, operations research, programming, actuarial mathematics, Statistik, operationsanalys, programmering, aktuariematematik
- language
- Swedish
- id
- 1644212
- date added to LUP
- 2008-08-18 00:00:00
- date last changed
- 2010-08-05 12:39:37
@misc{1644212,
abstract = {{A statistical analysis has been performed on a pharmacological study from the Lung department of Medical clinic, UsiL. The intention of the study was to explore, especially from a pallative aspect, treatment of exceptional fluid manifestations in pleura caused by cancer.
The patients were recruited between 1993 and 1997. They were randomized either to the drug Atabrine or to the drug Bleomycin. However due to the characteristics of the drugs it was not possible to perform this study as a double blind study. Except for an anomaly in one age group and in one gender group, we have found no signs or statistical indications that the randomization has been perfomed in an improper way. In this study it is the relapse rate that stands out. Patients treated with Bleomycin has a significant higher relapse rate than those treated with Atabrine (p=0.009). From a pallative aspect this is an important result.
With oddsratio over radiographic evidences of pleural disease there could be found a significant difference in lung quality between the two groups. Patients treated with Atabrine has a significant higher oddsratio, 1.62, to achieve the highest quality (p=0.0374).
The survival times could be followed all the way for all patients. No significant difference in the survival functions or the median survival times between the two treatments, Atabrine and Bleomycin, were found.}},
author = {{Arvastson, Per}},
language = {{swe}},
note = {{Student Paper}},
title = {{Medicinsk limning av lungsäcken}},
year = {{2008}},
}